ONWARD Medical, a pioneering company in the field of neuromodulation and rehabilitation, has announced that the US Food and Drug Administration (FDA) has cleared its ARC-EX Therapy System for home use, significantly enlarging the US market opportunity for hospitals and rehabilitation providers catering to individuals with spinal cord injuries (SCI). The ARC-EX System is now the first and only FDA-cleared technology proven to improve hand strength and sensation in people with SCI, enabling an entirely new model of home-based rehabilitation and follow-up care that promises to redefine mobility care delivery in the American hospital sector.

This milestone approval follows the company's recent attainment of the CE Mark certification, underscoring ARC-EX's clinical and technological credibility in both the US and European markets. According to ONWARD Medical, this clearance will allow care teams and hospitals to extend the therapeutic benefits of ARC-EX beyond controlled clinical environments, offering personalized, scalable rehabilitation directly in patients’ homes. This transformation holds both clinical and operational implications for hospital management teams striving to enhance long-term outcomes, reduce readmissions, and drive patient engagement outside the traditional acute care setting.

The FDA’s 510(k) clearance expansion for home use comes on the heels of robust clinical evidence. The LIFT Home Study, published in Neurology: Clinical Practice, demonstrated that continued ARC-EX Therapy use at home maintained and even extended gains achieved through in-clinic therapy. As a result, rehabilitation and mobility specialists as well as hospital administrators are now positioned to integrate digital therapy monitoring, remote support tools, and coordinated patient management into hospital discharge pathways and outpatient programs, reflecting a broader trend in the move toward digitized and patient-centered care models.

Financially, ONWARD Medical reported Q3 revenues exceeding EUR 1.7 million, indicating growing adoption of its platform and strategic confidence in further US expansion. Recent successful capital raises—surpassing EUR 50 million—further provide the company a strong runway to accelerate home-based rehabilitation adoption and invest in supporting hospital partners with training, support, and integration resources.

Leadership at ONWARD Medical outlined plans to build on this momentum by initiating the Empower BP global pivotal study—following a newly approved Investigational Device Exemption (IDE) for the ARC-IM System. This upcoming trial aims to address blood pressure instability in SCI patients, a development that could introduce additional avenues for hospital system participation in cutting-edge rehabilitation and cardiovascular recovery care. The first patient enrollment is anticipated by year’s end, with additional research implantations targeting new future indications—including for mobility post-SCI and in Parkinson’s disease.

For US hospitals, rehabilitation directors, and procurement leaders, this development marks a critical opportunity to differentiate services through access to proven, scalable neurorehabilitation technologies. It also necessitates evaluation of new home care protocols, tele-rehabilitation capabilities, and staff training on remote monitoring systems, aligning with the broader digital transformation agenda in the sector. Ultimately, as ARC-EX Therapy becomes more broadly available for home use, hospitals and rehabilitation centers are expected to play a central role in patient onboarding, clinical monitoring, and value demonstration for payers and referring physicians, setting new standards of care in neurorehabilitation across the American region.